Share This Article:

Cardiac Toxicity of Azole Antifungals

Abstract Full-Text HTML XML Download Download as PDF (Size:558KB) PP. 362-368
DOI: 10.4236/pp.2013.43052    4,547 Downloads   6,824 Views   Citations

ABSTRACT

Cardiac toxicity is an uncommon side effect of anti-fungal therapy. Until the recent reports of itraconazole (ITZ) associated cardiac failure, amphotericin was the antifungal most frequently reported with arrhythmias. We evaluated the cardiac effect of azole antifungals, specifically ITZ, and possible mechanisms of toxicity. Ex vivo live-heart studies were performed utilizing Sprague Dawley rats. Short exposure (<5 minutes), random crossover, dose ranging studies were performed with each pharmacologic agent. ITZ focused trials also included dose ranging utilizing a non-crossover design. The only azole found to have significant toxicity was ITZ. At ITZ ~ ED25 (2 - 2.5 ug/mL) exposures, contractility decreased by 22.2% ± 15.7% and amplitude of left ventricular pressure decreased by 11% ± 0.17%. Electron micrograph and alterations in mitochondrial respiration suggest mitochondrial toxicity as an underlying mechanism. In conclusion, ITZ was associated with reductions in contractility, possibly secondary to mitochondrial dysfunction and dilated cardiomyopathy.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

J. Cleary, K. Stover, J. Farley, W. Daley, P. Kyle and J. Hosler, "Cardiac Toxicity of Azole Antifungals," Pharmacology & Pharmacy, Vol. 4 No. 3, 2013, pp. 362-368. doi: 10.4236/pp.2013.43052.

References

[1] S. R. Ahmad, S. J. Singer and B. G. Leissa, “Congestive Heart Failure Associated with Itraconazole,” Lancet, Vol. 357, No. 9270, 2001, pp. 1766-1767.
[2] Institute of Laboratory Animal Resources (US) and Committee on Care and Use of Laboratory Animals, “Guide for the Care and Use of Laboratory Animals,” Public Health Service, US Department of Health and Human Services, Bethesda, 1996.
[3] Code of Federal Regulations Title 9, “Animals and Animal Products,” Animal Welfare, Chapter 1, Subchapter A, Parts 1 and 3, 2009.
[4] H. Liu, Q. Zheng and J. M. Farley, “Antimuscarinic Actions of Anti-histamines on the Heart,” Journal of Biomedical Science, Vol. 13, No. 3, 2006, pp. 395-401.
[5] J. D. Cleary, J. Hayman, J. Sherwood, G. P. Lasala and T. Piazza-Hepp, “Amphotericin B Overdose in Pediatric Patients with Associated Cardiac Arrest,” The Annals of Pharmacotherapy, Vol. 27, No. 6, 1993, pp.715-719.
[6] P. J. Danaher, M. K. Cao, G. M. Anstead, M. J. Dolan and C. C. DeWitt, “Reversible Dilated Cardiomyopathy Related to Amphotericin B Therapy,” Journal of Antimicrobial Chemotherapy, Vol. 53, No. 1, 2004, pp.115117. doi:10.1093/jac/dkg472
[7] M. Tofukuji, C. Metais, S. Y. Wang, S. L. Alper and F. W. Sellke, “Clotrimazole is a Potent Vasodilator of the Rat Coronary Microcirculation,” Journal of Surgical Research, Vol. 77, No. 1, 1998, pp. 6-10. doi:10.1006/jsre.1998.5320
[8] M. J. Hernandez-Benito, R. Macianskiene,K. R. Sipido, W. Flameng and K. Mubagwa, “Suppression of Transient Outward Potassium Currents in Mouse Ventricular Myocytes by Imidazole Antimycotics and by Glybenclamide,” Journal of Pharmacology and Experimental Therapeutics, Vol. 208, No. 2, 2001, pp. 598-606.
[9] I. M. Fearon, S. G. Ball and C. Peers, “Clotrimazole Inhibits the Recombinant Human Cardiac L-type Ca2+ Channel α1C Subunit,” British Journal of Pharmacology, Vol. 129, No. 3, 2000, pp. 547-554. doi:10.1038/sj.bjp.0703106
[10] B. Tunctan, S. Altug, O. Uludag and N. Abacioglu, “Effects of Econazole on Receptor-Operated and Depolarization-Induced Contractions in Rat Isolated Aorta,” Life Sciences, Vol. 67, No. 19, 2000, pp. 2393-2401. doi:10.1016/S0024-3205(00)00822-5
[11] “Sporonox [Package Insert],” Raritan, Ortho Biotech Products, L.P., New York, 2009.
[12] “Advisory for Fungal Drugs,” FDA Consumer, Vol. 35, No. 4, 2001, p. 4.
[13] V. M. Figueredo, “Chemical Cardiomyopathies: The Negative Effects of Medications and Non-Prescribed Drugs on the Heart,”American Journal of Medicine, Vol. 124, No. 6, 2011, pp. 480-488.
[14] M. D. Liedtke, J. K. Vandaveer, R. A. Greenfield and S. M. Lockhart, “Congestive Heart Failure Exacerbation Secondary to Itraconazole Therapy,”Infectious Diseases in Clinical Practice, Vol. 19, No. 6, 2011, pp. e19-e20. doi:10.1097/IPC.0b013e3182156810
[15] C. B. Brown, J. S. Raniolo and T. Kuberski, “Life-Threatening Heart Failure Associated with Itraconazole,” Infections in Medicine, Vol. 25, No. 6, 2008, pp. 1-3.
[16] G. N. Mattiuzzi, G. Alvarado, F. J. Giles, L. OstroskyZeichner, J. Cortes and S. O’brien, et al., “Open-Label, Randomized Comparison of Itraconazole versus Caspofungin for Prophylaxis in Patients with Hematologic Malignancies,”Antimicrobial Agents and Chemotherapy, Vol. 50, No. 1, 2006, pp. 143-147. doi:10.1128/AAC.50.1.143-147.2006
[17] N. Paleiron, N. Bizien, U. Vinsonneau, M. Andre and F. Grassin, “Acute Cardiac Failure Due to Itraconazole,” Revue des Maladies Respiratoires, Vol. 28, No. 3, 2011, pp. 352-354. doi:10.1016/j.rmr.2010.08.014
[18] P. Richardson, W. McKenna and M. Bristow, et al., “Report of the 1995 World Health Organization/International Society and Federation of Cardiology Task Force on the Definition and Classification of Cardiomyopathies,” Circulation, Vol. 93, 1996, pp. 841-842. doi:10.1161/01.CIR.93.5.841
[19] C. B. Maxwell and A. T. Jenkins. “Drug-Induced Heart Failure,” American Journal of Health-System Pharmacy, Vol. 68, No. 19, 2011, pp. 1791-804.
[20] J. A. Philips, F. M. Marty, R. M. Stone, B. A. Koplan, J. T. Katz and L. R. Baden, “Torsades de Pointes Associated with Voriconazole Use,” Transplant Infectious Disease, Vol. 9, No. 1, 2007, pp. 33-36.
[21] R. J. Rodriguez and D. Acosta Jr., “Inhibition of Mitochondrial Function in Isolated Rate Liver Mitochondria by Azole Antifungals,” Journal of Biochemical Toxicology, Vol. 11, No. 3, 1996, pp. 127-31. doi:10.1002/(SICI)1522-7146(1996)11:3<127::AID-JBT4>3.0.CO;2-M
[22] D. P. Dickinson, “The Effects of Miconazole on Rat Liver Mitochondria,” Biochemical Pharmacology, Vol. 26, No. 6, 1977, pp. 541-542.
[23] S. Gentry-Smetana, D. Redford, D. Moore and D. F. Larson, “Direct Effects of Volatile Anesthetics on Cardiac Function,” Perfusion, Vol. 23, No. 1, 2008, pp. 43-47. doi:10.1177/0267659108094528

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.